Soluble (s) ST2 has been proposed as a useful biomarker for heart failure (HF) patient
management. Myocardial damage or mechanical stress stimulate sST2 release. ST2 …

An increasing awareness of the disease, new diagnostic tools and novel therapeutic
opportunities have dramatically changed the management of patients with amyloid …

Abstract Cardiovascular diseases, including Heart Failure (HF), remain a leading global
cause of mortality, often evading early detection. In this context, accessible and effective risk …

Heart failure with preserved ejection fraction (HFpEF) is highly prevalent and associated
with worse cardiovascular outcomes. The pathophysiology of HFpEF mostly relies on the …

Background Sodium glucose co-transporter 2 inhibitors (SGLT2i) are one of the
cornerstones of heart failure (HF) therapy. While benefits in terms of HF hospitalizations and …

Major international practice guidelines recommend the use of a combination of 4 medication
classes in the treatment of patients with heart failure with reduced ejection fraction (HFrEF) …

Abstract Purpose of Review An evidence for lipid lowering therapy in heart failure is briefly
summarized in this review. Recent Findings Heart failure therapy is based on recent …

Background The purpose of this study was to develop and validate a machine learning (ML)
based prediction model for the risk of heart failure (HF) in patients with prediabetes or …

In the last years, major progress has occurred in heart failure (HF) management. The 2023
ESC focused update of the 2021 HF guidelines introduced new key recommendations …

Heart failure (HF) with preserved ejection fraction (HFpEF) causes a progressive limitation of
functional capacity, poor quality of life (QoL) and increased mortality, yet unlike HF with …